David Vann, MD
Internal Medicine · Sharpsburg, GANPI 1760466742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.
Across 145 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$325
- Pfizer$268
- Novo Nordisk$245
- GSK$240
- Radius Health, Inc.$168
- AbbVie$163
- plus $1K from 24 others
Across 9 payments — averaging $7185.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$65K
What the payments were for
- Food & beverage$2,42194%
- Education$1636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 14 | $325 |
| Pfizer | 14 | $268 |
| Novo Nordisk | 13 | $245 |
| GSK | 14 | $240 |
| Radius Health, Inc. | 15 | $168 |
| AbbVie(2 entities) | 10 | $163 |
| AstraZeneca | 9 | $141 |
| Boehringer Ingelheim | 6 | $108 |
| Sanofi-aventis U.S. LLC | 5 | $104 |
| Sumitomo Pharma America, Inc. | 5 | $102 |
| Dexcom, Inc. | 5 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| Astellas Pharma US Inc | 4 | $81 |
| Amgen(2 entities) | 5 | $72 |
| Novartis | 2 | $38 |
| Bayer | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $22 |
| Neos Therapeutics, LP | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Merck | 1 | $13 |
| Mannkind Corporation | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
How this compares
$2,585 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $247,707 |
| EliquisApixaban | 212 | $206,376 |
| JardianceEmpagliflozin | 140 | $168,947 |
| MounjaroTirzepatide | 124 | $158,324 |
| JanuviaSitagliptin Phosphate | 80 | $73,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $70,615 |
| TrulicityDulaglutide | 41 | $54,256 |
| FarxigaDapagliflozin Propanediol | 41 | $44,495 |
| XareltoRivaroxaban | 35 | $41,765 |
| MyrbetriqMirabegron | 50 | $40,858 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $34,353 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $33,488 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $20,049 |
| LinzessLinaclotide | 19 | $18,238 |
| RybelsusSemaglutide | 12 | $17,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $245 | $265,337173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $325 | $212,580165 claims |
| PfizerEliquis | $268 | $206,376212 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $108 | $202,750167 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $240 | $83,994123 claims |
| MerckJanuvia, Belsomra, Lagevrio (Eua) | $13 | $83,609103 claims |
| AstraZenecaFarxiga | $141 | $44,49541 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $40,85850 claims |
| AbbVieLinzess, Restasis, Synthroid | $163 | $33,294122 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $102 | $9,39712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Sharpsburg
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.